RecruitingNCT07586995

A Post-Market Assessment of the Safety and Performance of the TriClip™ System

A Post-Market Assessment of the Safety and Performance of the TriClip™ System (TREAT TR)

Sponsor

Abbott Medical Devices

Enrollment

1,000 participants

Start Date

Jun 1, 2026

Study Type

OBSERVATIONAL

Conditions

Tricuspid Regurgitation (TR)

Summary

The objective of the TREAT TR study is to confirm the safety and performance of the TriClip System for tricuspid TEER in a contemporary, real-world setting, using the commercially available device in accordance with its approved indications for use.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Tricuspid Transcatheter Edge-to-Edge Repair (TEER) for people with tricuspid regurgitation (tr). The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.